最新消息

Pharmacy expert opposes diluting BioNTech jabs for the very young

標籤: BioNTech , COVID-19 , COVID-19 Vaccines

2022 月 08 月 12 日

Hong Kong should not dilute the adult 30mg doses of BioNTech vaccines to one-tenth - or 3mg - for children six months to five years old, said William Chui Chun-ming, President of the Society of Hospital Pharmacists of Hong Kong.  

 

His comments came after health authorities announced that children between six months and three years old may receive mainland-made Sinovac vaccine from Wednesday, while authorities engage in talks with BioNTech’s maker to buy its toddler version that will give parents a second inoculation option.  

BioNTech has separate vaccines for adults, children, and toddlers. The toddler version is one-third of the children’s version.  

The government’s vaccine expert advisors have earlier suggested that authorities dilute the adult BioNTech dosage for kids’ use if the city cannot get ahold of the toddler version BioNTech vaccines.   

Speaking on a radio program this morning, the pharmacy expert backs authorities’ decision to inoculate young children with the Sinovac vaccine, which he believed the decision was made after a comprehensive review of relevant data.  

As for the BioNTech vaccine, Chui advised against diluting.  

He said the dosage for children below three is too low, and a slight deviation may have a massive effect on the safety and effectiveness of the jabs.  

“That is because BioNTech vaccine uses mRNA technology and tiny nanoparticles,” Chui said. “If only a very small amount of nanoparticles are used after dilution, we would be concerned about the vaccine’s stability as it may not trigger the sufficient immune response.”  

Chui said the toddler version jabs were available in places like Singapore and European countries, whereas the manufacturer has previously stated they could ensure sufficient supply.  

He called on the SAR government to explain to the general public the reason for the hold-up in providing the toddler BioNTech jabs.

 

 

[文章及圖片轉載The Standard 03/08/2022 連結]


分類文章標籤: BioNTech , COVID-19 , COVID-19 Vaccines


其他相關文章

Call to play it...

2022 月 02 月 07 日

Hong Kong should wait for more data before deciding whether ...

復星研發中心總裁接受《經濟》專...

2021 月 02 月 10 日

由中國復星醫藥/德國藥廠 BioNTech 合作研發的新型冠狀病毒疫苗,最快本月底抵港。復星醫藥全球研發中心總裁回愛民接...

復星/BioNTech疫苗料下...

2021 月 01 月 28 日

港府已「認可」復星/BioNTech疫苗在香港「緊急使用」,預計下月下旬由德國運抵香港。雖然外國曾出現接種後死亡個案,不...

GOVT SHOULD ACT...

2021 月 10 月 07 日

A pharmacists’ association said on Monday that a new drug fo...

輝瑞研新藥服一粒可減重症 許樹...

2021 月 04 月 30 日

美國藥廠輝瑞(Pfizer)正研發治療COVID-19新口服藥物,是一種蛋白酶抑制劑,適用於感染初期,或可減低患者需入院...

【和你抗疫】酒精搓手液濃度勿超...

2020 月 03 月 06 日

新型冠狀病毒(COVID-19)肆虐,公眾對消毒用品需求大增,令市面上的酒精搓手液被一掃而空。有見及此,有專家及大學教授...

更多
更多